Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687123 · ClinicalTrials.gov registry record · Phase 1
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
A Phase 1 study of Pancreatic Neoplasm and Metastatic Pancreatic Neuroendocrine Tumor, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT05687123 is a Phase 1 study of Pancreatic Neoplasm and Metastatic Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 658-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT05687123, a Phase 1 study of Pancreatic Neoplasm and Metastatic Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG Lutetium Lu 177 Dotatate
Study Locations (10)
Missouri
- Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
- Siteman Cancer Center at Christian Hospital - St Louis
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Illinois
- Memorial Hospital East - Shiloh
Ontario
- University Health Network-Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2026-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05687123
The ClinicalTrials.gov registry entry for NCT05687123 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05687123 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Missouri, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05687123 about?
NCT05687123 is a clinical study titled "Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors". This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blo...
What is the current status of trial NCT05687123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-08-14. Estimated completion is 2026-12-14.
What conditions does trial NCT05687123 study?
This clinical trial studies the following conditions: Pancreatic Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT05687123?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Lutetium Lu 177 Dotatate (DRUG).
Who is sponsoring clinical trial NCT05687123?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05687123 being conducted?
This trial has 10 study locations across California, Illinois, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
RECRUITING · Phase 1
-
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
COMPLETED · Phase 1
-
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
COMPLETED · Phase 1
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
Explore more on PlainTrial
Pancreatic Neoplasm
All registered trials for this condition
Metastatic Pancreatic Neuroendocrine Tumor
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.